Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Phase II Study with Cetuximab and Radiation Therapy for Patients with Surgically Resectable Esophageal and GE Junction Carcinomas Hoosier Oncology Group G05-92

A Phase II Study with Cetuximab and Radiation Therapy for Patients with Surgically Resectable... in Gap 1 cell-cycle arrest, and radiation results in Gap 2 cell- No. 4557) was published at the 2009 American Society of Clinical cycle arrest, Gap 1 and Gap 2 being part of the interphase Oncology Annual Meeting (J Clin Oncol 2009;8:1425–1429). segment of cell growth. In preclinical models, EGFR inhi- Address for correspondence: Carlos R. Becerra, MD, Texas Oncology, Baylor Sammons Cancer Center, 3410 Worth Street, Dallas Texas 75246. E-mail: bition enhances radiation-induced apoptosis, inhibits repair carlos.becerra@usoncology.com of radiation-induced DNA damage, and inhibits formation Copyright © 2013 by the International Association for the Study of Lung of new blood vessels. The radio-sensitizing effect of cetux- Cancer imab has already been tested in patients with squamous cell ISSN: 1556-0864/13/0811-1425 Journal of Thoracic Oncology  • Volume 8, Number 11, November 2013 1425 ® Becerra et al. Journal of Thoracic Oncology  • Volume 8, Number 11, November 2013 carcinomas of the head and neck, with improvement in local The initial dose of cetuximab was administered at control, progression-free and overall survival over radiation 400 mg/m intravenously over 120 minutes followed by 7 2 therapy alone. weekly infusions of cetuximab at 250 mg/m over 60 min- Herein, we present the results of a single-arm, open- utes. Cetuximab was administered weekly for two doses. label, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

A Phase II Study with Cetuximab and Radiation Therapy for Patients with Surgically Resectable Esophageal and GE Junction Carcinomas Hoosier Oncology Group G05-92

Choy, Hak
Journal of Thoracic Oncology , Volume 8 (11) – Nov 1, 2013
Download PDF
5 pages

Loading next page...
 
/lp/wolters-kluwer-health/a-phase-ii-study-with-cetuximab-and-radiation-therapy-for-patients-w8dsdr8uZi

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2013 by the International Association for the Study of Lung Cancer
ISSN
1556-0864

Abstract

in Gap 1 cell-cycle arrest, and radiation results in Gap 2 cell- No. 4557) was published at the 2009 American Society of Clinical cycle arrest, Gap 1 and Gap 2 being part of the interphase Oncology Annual Meeting (J Clin Oncol 2009;8:1425–1429). segment of cell growth. In preclinical models, EGFR inhi- Address for correspondence: Carlos R. Becerra, MD, Texas Oncology, Baylor Sammons Cancer Center, 3410 Worth Street, Dallas Texas 75246. E-mail: bition enhances radiation-induced apoptosis, inhibits repair carlos.becerra@usoncology.com of radiation-induced DNA damage, and inhibits formation Copyright © 2013 by the International Association for the Study of Lung of new blood vessels. The radio-sensitizing effect of cetux- Cancer imab has already been tested in patients with squamous cell ISSN: 1556-0864/13/0811-1425 Journal of Thoracic Oncology  • Volume 8, Number 11, November 2013 1425 ® Becerra et al. Journal of Thoracic Oncology  • Volume 8, Number 11, November 2013 carcinomas of the head and neck, with improvement in local The initial dose of cetuximab was administered at control, progression-free and overall survival over radiation 400 mg/m intravenously over 120 minutes followed by 7 2 therapy alone. weekly infusions of cetuximab at 250 mg/m over 60 min- Herein, we present the results of a single-arm, open- utes. Cetuximab was administered weekly for two doses. label,

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Nov 1, 2013

There are no references for this article.